Patent ID: 11939327
Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC C

Claim 10:
11. The method according to claim 9, wherein
R1 and R2 are each independently
(1) a hydrogen atom,
(2) a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from
(a) a cyano group, and
(b) a C3-6 cycloalkyl group, or
(3) a tetrahydropyranyl group, or
R1 and R2 are bonded to each other to form, together with the adjacent nitrogen atom,
(1) a morpholine ring optionally further substituted by 1 to 3 substituents selected from
(a) a halogen atom, and
(b) a C1-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(2) an oxazepane ring optionally further substituted by 1 to 3 halogen atoms,
(3) an azetidine ring optionally further substituted by 1 to 3 halogen atoms,
(4) a pyrrolidine ring optionally further substituted by 1 to 3 C1-6 alkoxy groups,
(5) a piperidine ring optionally further substituted by 1 to 3 C1-6 alkoxy groups, or
(6) a 5-oxa-8-azaspiro[2.6]nonane ring;
R3 is a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a cyano group, and
(c) a C1-6 alkoxy group;
X is CR4 or N;
R4 is
(1) a hydrogen atom,
(2) a halogen atom, or
(3) a C1-6 alkyl group;
R5 is
(1) a hydrogen atom, or
(2) a C1-6 alkyl group;
R6 is a hydrogen atom; and
Ring A is
(1) a benzene ring optionally further substituted by 1 to 4 substituents selected from (i) a halogen atom, and (ii) a C1-6 alkoxy group, or
(2) a pyridine ring optionally further substituted by 1 to 4 halogen atoms.